(Oslo, Norway, 18 July 2014) Bionor Pharma ASA (OSE: BIONOR) announces that results of the ad hoc, subset analysis of the large Phase II clinical study of therapeutic HIV vaccine candidate Vacc-4x – which identified C5/gp41 antibody levels as a potential biomarker for improved response to Vacc-4x – were presented today as a poster at the AIDS …
•HDAC inhibitor (HDACi) Istodax® (romidepsin) successfully reactivated (“kick”) HIV in patients •Treatment of Istodax® was safe and well tolerated •Part B of the REDUC study to enroll patients in Q2 2014 (Oslo, Norway, 12 May 2014) Bionor Pharma ASA (OSE: BIONOR) announces that the part A of the REDUC study has successfully completed. The objective …
(Oslo 1 April, 2014) Bionor Pharma ASA (OSE: BIONOR) announced today the completion of enrollment of patients for part A of the Phase I/II REDUC study. The trial combines Bionor Pharma’s lead vaccine candidate Vacc-4x and the HDAC inhibitor Istodax® (romidepsin). Part A of the study will establish the optimal dose of Istodax in a …
